PF-562271

N/A

Report date: 2025/06/10 17:55:08
NME

Base Information

Drug NamePF-562271
Drug Alias NamePF-431396PF-562271PF-271PF-00562271VS-6062
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFocal adhesion kinase 1 inhibitorsFocal adhesion kinase 2 inhibitors
TargetsFocal adhesion kinase 1Focal adhesion kinase 2
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVerastem Inc
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A